Results 51 to 60 of about 42,124 (246)

Downregulation of CXXC Finger Protein 4 Leads to a Tamoxifen-resistant Phenotype in Breast Cancer Cells Through Activation of the Wnt/β-catenin Pathway

Translational Oncology, 2020
Tamoxifen is a successful endocrine therapy drug for estrogen receptor–positive (ER+) breast cancer. However, resistance to tamoxifen compromises the efficacy of endocrine treatment.
Yijie Fu, Zhu Wang, Chuanxu Luo, Yu Wang, Yanping Wang, Xiaorong Zhong, Hong Zheng   +6 more
doaj   +1 more source

Interaction of tamoxifen with the multidrug resistance P-glycoprotein [PDF]

British Journal of Cancer, 1995
Tamoxifen is an anti-oestrogen which is currently being assessed as a prophylactic for women at high risk of breast cancer. Taxoxifen has also been shown to reverse multidrug resistance in P-glycoprotein (P-gp)-expressing cells, although the mechanism of action is unknown. In this study we demonstrate that tamoxifen interacts directly with P-gp. Plasma
R, Callaghan, C F, Higgins
openaire   +2 more sources

Overcoming tamoxifen resistance in oestrogen receptor-positive breast cancer using the novel thiosemicarbazone anti-cancer agent, DpC

, 2020
Background and Purpose: Breast cancer is the leading cause of death in women worldwide, with resistance to current therapeutic strategies, including tamoxifen, causing major clinical challenges and leading to more aggressive and metastatic disease.
Patric J. Jansson, Lim, Syer C, Kovacevic, Zaklina, Rumeza Hanif, Park, Kyung Chan, Des R. Richardson, Zaklina Kovacevic, Hanif, Rumeza, Sundus N. Maqbool, Kyung Chan Park, Maqbool, Sundus N, Richardson, Des R, Jansson, Patric J, Syer C. Lim   +13 more
core   +1 more source

Chemical approaches to targeting drug resistance cancer stem cells [PDF]

, 2016
STEMCHEM is a COST action aiming to target causes of drug resistance in cancer stem cells. Cancer stem cells are cells which are believed to be responsible for the larger part of the regenerative capacity of cancers.
Micallef, Neville, Cassar, Analisse, Stipourou, Iona, Blaire Theuma, Krystle, Suleiman, Sherif, Schembri-Wismayer, Pierre, Passarella, Daniele   +6 more
core   +1 more source

Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas [PDF]

Anti-Cancer Drugs, 2015
Tamoxifen, a selective estrogen receptor modulator, is widely used in the chemotherapy of estrogen receptor-positive breast cancer. Recent studies have indicated that tamoxifen might have a potential chemotherapeutic effect on glioma. In the present study, we determined the chemotherapeutic action of tamoxifen on human glioma cell lines. Methylation of
Weiliang, He, Ran, Liu, Shao-Hua, Yang, Fang, Yuan   +3 more
openaire   +2 more sources

Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer.

PLoS ONE, 2016
AimThe estrogen receptor coactivator Amplified in Breast Cancer 1 (AIB1) has been associated with an improved response to adjuvant tamoxifen in breast cancer, but also with endocrine treatment resistance.
Sara Alkner, Pär-Ola Bendahl, Anna Ehinger, Kristina Lövgren, Lisa Rydén, Mårten Fernö   +5 more
doaj   +1 more source

Tamoxifen resistance mechanisms in breast cancer treatment

, 2020
Therapies targeting estrogen receptor (ER) are being widely used to treat ER+ breast cancer patients. Despite early detection and improved survival outcomes, tamoxifen resistance, either intrinsic or acquired- is a major obstacle in effective disease ...
Asima Tayyeb
core   +1 more source

Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer [PDF]

, 2008
Elevated c-Src protein expression has been shown in breast cancer and <i>in vitro</i> evidence suggests a role in endocrine resistance. To investigate whether c-Src is involved in endocrine resistance, we examined the expression of both total
Cooke, T.G., Tatarov, O., Tovey, S, O Tatarov, V Brunton, T G Cooke, McDuff, E, E J Campbell, McDuff, E., Tovey, S., Edwards, J, E McDuff, Brunton, V.G., S Tovey, Brunton, V, J Edwards, Edwards, J., Campbell, E J, Tatarov, O, Campbell, E.J., Cooke, T G   +20 more
core   +1 more source

Subtype‐specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers

Molecular Oncology, EarlyView.
This study employed machine learning methodologies to perform the subtype‐specific classification of RNA‐seq data sets, which are mapped on enhancers from TCGA‐derived breast cancer patients. Their integration with gene expression (referred to as ProxCReAM eRNAs) and chromatin accessibility profiles has the potential to identify lineage‐specific and ...
Aamena Y. Patel, Peyman Zarrineh, Nathnael T. Tuffa, Jigar H. Sheth, Sumitra Mohan, Mudassar Iqbal, Sankari Nagarajan   +6 more
wiley   +1 more source

Development of resistance towards artesunate in MDA-MB-231 human breast cancer cells. [PDF]

, 2011
Breast cancer is the most common cancer and the second leading cause of cancer death in industrialized countries. Systemic treatment of breast cancer is effective at the beginning of therapy.
Ulrich Pfeffer, Killian, Peter H., Fichtner Iduna, Efferth, Thomas, Iduna Fichtner, Pfeffer Ulrich, Pfeffer, U., Emanuel Kronski, Bachmeier Beatrice, Killian, P.H., Fichtner, I., Beatrice Bachmeier, Bachmeier, B., Thomas Efferth, Kronski, Emanuel, Efferth Thomas, Kronski, E., Pfeffer, Ulrich, Fichtner, Iduna, Bachmeier, Beatrice, Peter H. Killian, Peter H Killian, Efferth, T., Kronski Emanuel, Killian Peter H.   +24 more
core   +1 more source